Blue Jet Healthcare Approves Q1 Results, Re-appoints Key Directors and Auditors
Blue Jet Healthcare Ltd has announced the outcome of its Board meeting held on August 3, 2026, approving the unaudited standalone financial results for the first quarter ended June 30, 2026. The company also made decisions regarding the reappointment of key management personnel and statutory auditors, alongside declaring a dividend for the previous financial year.The Board meeting approved the re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman. He is proposed to serve a five-year term, effective from April 13, 2027 to April 12, 2032, pending shareholder approval at the ensuing Annual General Meeting (AGM).
Furthermore, Mr. Shiven Akshay Arora was re-appointed as the Managing Director for another five years, effective from April 13, 2027 to April 12, 2032, also subject to AGM ratification.
The company also approved the reappointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of five consecutive years. This reappointment will extend until the conclusion of the 63rd Annual General Meeting of the Company in the financial year 2030-31, pending shareholder approval.
Financial Performance Summary
The unaudited financial results for the quarter ended June 30, 2026, showed key operational figures across various periods. The company's business segments include manufacturing Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, and APIs used in Pharmaceutical and Healthcare products.The performance details of the first quarter are presented below:
| Particular | 30-06-2026 (Unaudited) | 31-03-2026 (Audited) | 30-06-2025 (Unaudited) | 31-03-2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 2,931.13 fin million | 2,346.68 fin million | 3,547.58 fin million | 9,473.21 fin million |
| Total Income (Revenue + Other Income) | 3,083.50 fin million | 2,575.88 fin million | 3,630.12 fin million | 10,159.75 fin million |
| Total Expenses | 2,024.04 fin million | 1,704.39 fin million | 2,401.52 fin million | 6,834.63 fin million |
| Profit before Tax | 1,059.46 fin million | 871.49 fin million | 1,228.60 fin million | 3,325.12 fin million |
| Total Tax Expense | 276.82 fin million | 228.05 fin million | 316.90 fin million | 846.96 fin million |
| Profit for the Period | 782.64 fin million | 643.44 fin million | 911.70 fin million | 2,478.16 fin million |
Audit Review and Shareholder Matters
The unaudited results have been reviewed by the Statutory Auditor, M/s KKC & Associates LLP. The firm confirmed that based on their review conducted in accordance with SRE 2410, nothing had come to their attention that suggested the accompanying Statement contained any material misstatement.In addition to the operational updates, the Board of Directors determined a dividend payment for the financial year 2025-26. A dividend of Rs. 1.2/- (@ 60%) per Equity Share, having a face value of Rs. 2/- each, was recommended by the Board and is subject to shareholder approval. The record date set for this dividend entitlement is September 14, 2026.
The company has scheduled its 58th Annual General Meeting (AGM) for September 21, 2026.
BLUEJET Stock Price Movement
Blue Jet Healthcare Limited sheds value as of 12:53 PM, with shares dropping 3.53% to trade at ₹604.15 after losing ₹22.10 in intra-day trading. The stock is seeing a volume of approximately 1.85 million shares during the live market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: